We hypothesize that the AR/DPYSL5/EZH2/PRC2 axis is a novel mechanism underlying prostate cancer progression to t-NEPC, and it is important to further elucidate the theranostic potential of DPYSL5 and explore any pharmacological strategies that could manipulate its expression. This evidence concerns the gene EZH2 and prostate carcinoma.